% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • maxdad01 maxdad01 Apr 16, 2013 1:17 PM Flag

    Q1 EPS ESTIMATE IS $1.19 NOT $1.09 AND

    Lowered from $1.29 because of some delays at new support center as indicated by company. Those delays should cause NO decrease in annual EPS ($6.79) as they will simply roll forward to Q2, which will be up significantly and Q3 & Q4 will be EXPLOSIVE GROWTH IN TOP AND BOTTOM LINE as over 100 new reps hit full productivity!!! IF BOTH NS AND RHEUMATOLOGY (NS is virtually certain) takes off (already has started) then $6.79 will be way too conservative...It is based on STRONG GROWTH in NS and decent growth in Rheumatology.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You seem to talk a lot about earnings growth and I keep asking myself how much of this is from buying back stock?

      I take it your not factoring this in?

      So what happens to your numbers if the company buys in another say 7 million shares this year and again next and than the following?

      I would think this would blow your numbers to the moon.

      • 1 Reply to reason204
      • Stock buybacks and their accretive impact are far too difficult to estimate (for me or ANYONE) and even the company can't know because another acquisition (like Biovectra) could come along just as they were about to buy back X million shares (simply an example). So NO it is NOT calculated in my model at all. BUT buying the full 7 million shares would amount to 13-15% accretion so simply add back up to that times inherent EPS. BUT in turn remember that accretion then goes into the DCF for ALL "out" periods in determining valuation!!!

    • Q1 will be bad and so will be Q2
      and then there is too much uncertainty

      why would mr don bailey give a heck he already made his money

93.60+1.52(+1.65%)Aug 14 4:00 PMEDT